EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay
Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade; however, application of these assays in a regular setting is still poorly understood. In this study, we tested eight VPA analogues included in the EU-ToxRisk case study with the devTOXqP in vitro hPS cell platform and ranked their developmental toxicity potential.
Please fill out the form below to download the poster: